What information would Dr. Patterson provide in a PR? We already had a PR today with an update on the EIND and mild/moderate trial. NP did mention the possibility of a PR tomorrow regarding the 2b/3 trial. I’m assuming that PR state the first patient has been injected in the phase 2b/3 for severe patients. I don’t see how Dr. Paterson can include any new information in there and NP said they’re waiting to get 2 weeks of data from the first 10 patients in the EIND before releasing more of it.
“I have a feeling that if Dr. Bruce has some great info
What information would Dr. Patterson provide in a PR? We already had a PR today with an update on the EIND and mild/moderate trial. NP did mention the possibility of a PR tomorrow regarding the 2b/3 trial. I’m assuming that PR state the first patient has been injected in the phase 2b/3 for severe patients. I don’t see how Dr. Paterson can include any new information in there and NP said they’re waiting to get 2 weeks of data from the first 10 patients in the EIND before releasing more of it.
Top 10 Most Recent News Articles
Black Friday Doubt Grows: Just 54% Trust Real Deals
Do Shoppers Believe in Black Friday Anymore? You'd think by now, retailers would have cracked the code on building trust with their customers. But guess what? A fresh survey from Boston Consulting Group reveals only 54% of consumers buy the whole Black Friday discount story. That's barely more than flipping a coin. Promotion Fatigue: The Trust Buster Funny thing,...
Continue Reading
CStone, Kimia Collaboration Targets Solid Tumor Survival
Biotech Giants CStone and Kimia Unite Forces In the heart of China's biotechnology scene, the latest collaboration news to hit the wires is CStone Pharmaceuticals shaking hands with Kimia Therapeutics. Now, don't go tossing this aside as another run-of-the-mill partnership announcement. CStone's HKEX: 2616 ticker has got its eyes locked on an ambitious dance with Kimia,...
Continue Reading
Samsung Biologics Hits 'Negligible' ESG Risk Milestone
Samsung Biologics Achieves a Low-Risk Triumph You gotta hand it to Samsung Biologics for hitting a 'Negligible Risk' rating. Their latest score? A cool 9.0. That’s like walking into the pharmaceuticals room and getting a standing ovation. It's no small feat—climbing up from a 'Low Risk' rating to the top tier in Morningstar Sustainalytics' playbook. For us spectating...
Continue Reading
Emergency Surgery Verification Lowers Death Rates: Study
Diving into Emergency General Surgery Verification How often do you hear a hospital accreditation making a real difference? The latest report in JAMA Surgery suggests it’s more than just a plaque on the wall for some. We're talking about the American College of Surgeons (ACS) Emergency General Surgery Verification program, which links directly to better patient...
Continue Reading
Stellus Capital Set to Unveil Q3 Results: Key Details
Stellus Capital's Upcoming Financial Reveal: Stakes and Details November's not just bringing the cold breezes, folks; it's also ushering in the much-anticipated financial digits of Stellus Capital Investment Corporation's third quarter of 2026. Mark your calendars for November 9, after the stock market wraps up, when Stellus will drop its operational performance stats for...
Continue Reading
Life with PAH: A Journey of Awareness and Hope
Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...
Continue Reading
KFC Teams with Marvel for Record-Breaking Menu Launch
Movie Magic on the Menu When was the last time a bucket of fried chicken sent such ripple effects through pop culture? KFC's decision to sling Doctor Doom-inspired dishes across 100 countries smells like genius business mixed with a dash of the absurd. Just imagine: an empire of battered birds aligning with Marvel's latest cinematic heavy hitter, "Avengers: Doomsday." Now...
Continue Reading
AppLovin Faces Lawsuit: Investor Unrest Unfolds
Shaky Ground Beneath AppLovin's Feet Ah, the sweet smell of litigation in the tech space—it’s like déjà vu for seasoned market folks. Here we have AppLovin, nestled comfortably in San Francisco, now eying a saucy class-action lawsuit. We're looking at shareholders taking a firm stance against some arguably misleading claims. We're talking big deals with allegations...
Continue Reading
Singtel, Ericsson Push 6G Healthcare to the Forefront
Breaking Ground in Healthcare Tech Ah, what’s cooking in Singapore? On a day like today, when the tech giants Singtel and Ericsson get chummy with National University Health System (NUHS), we're looking at the kind of healthcare advancements that read like science fiction. They’ve signed an MOU to launch the National University XG AI Centre (NXAC) – a mouthful,...
Continue Reading
Lakefront Living: Steuben County's Twin Tales
Here’s how it is: choosing a lakefront home in Steuben County, Indiana, ain't just about picking a place with a killer view. It’s like buying a lifestyle package and you’d better know what you’re getting. An article by Tony Isa, the go-to real estate guru in these parts, puts the spotlight on Lake James and Clear Lake—but what matters is how each might wrangle...
Continue ReadingTop 5 Most Recently Viewed Articles
Keyo Elevates Rudy Dajie to CEO, Driving Innovative Payments
Keyo Appoints Rudy Dajie as New CEO for Advanced Payment Solutions Keyo has recently announced a game-changing leadership appointment with Rudy Dajie stepping into the role of Chief Executive Officer. In a world where artificial intelligence is rapidly evolving, the demand for enhanced security in biometric identification is greater than ever. Innovative Biometric...
Continue Reading
Final Call for $XPL Token Access: Join the XploraDEX Journey
Final Chance to Participate in $XPL Token Distribution The $XPL token distribution is entering its crucial final phase, marking an exciting moment for both investors and traders. As the presale of XploraDEX nears its closing date, many are eager to grab their share of the tokens before the opportunity slips away. This innovative platform, set on the XRP Ledger, has the...
Continue Reading
Promising Small-Cap Stocks on the Rise for Investors
Small-Cap Stocks on the Verge of Growth As 2024 progresses, many analysts have identified a resurgence in small-cap stocks, suggesting that this year could mark a turning point for these often-overlooked companies. With the economic landscape shifting, especially as interest rates stabilize, there is renewed hope for sectors that faced challenges in previous years....
Continue Reading
Eli Lilly's New Oral Diabetes Treatment Python Results Exceed Expectations
Eli Lilly's Groundbreaking Diabetes Treatment Trials Eli Lilly and Company (NYSE: LLY) has made significant advancements in the treatment of type 2 diabetes with their oral medication, orforglipron. Recent Phase 3 trials, ACHIEVE-2 and ACHIEVE-5, have demonstrated impressive results in controlling blood sugar levels among participants. ACHIEVE Trials Overview The...
Continue Reading
Experience Luxury and Performance with the 2025 LC 500 Convertible
Introducing the 2025 LC 500 Convertible The 2025 LC 500 Convertible marks another exciting development in the luxury automobile market, maintaining its prestige and allure. This model has undergone a few updates and is ready to impress enthusiasts and casual drivers alike. Standout Features of the 2025 Model This year's model comes with notable enhancements, including...
Continue Reading